Allurion cuts ~65% workforce, reports preliminary Q2 revenue ~$3M, shifts to GLP-1 combo therapy

ALLURION TECHNOLOGIES, INC.

2025-Q2 EPS reported -$1.79 revenue$8,959,000

Preliminary Q2 2025 revenue ~$3M, operating loss ~$7M, improved from $9.3M loss in Q2 2024; operating expenses down ~50% YoY.
Restructuring: workforce reduction of ~70 employees (~65% of total); estimated severance charges of ~$1.5M; completion expected by end of Q3 2025.
Signed term sheet with strategic partner for ex-US distribution and potential joint development of a GLP-1 drug-eluting intragastric balloon.
Submitted protocol to IRBs for prospective study on low-dose GLP-1 + Allurion Program for weight loss and muscle preservation; enrollment expected in 2025.
PMA application for Allurion Balloon accepted by FDA for evaluation.

item 2.02item 2.05item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.